0001104659-20-024698.txt : 20200326 0001104659-20-024698.hdr.sgml : 20200326 20200225150022 ACCESSION NUMBER: 0001104659-20-024698 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Passage BIO, Inc. CENTRAL INDEX KEY: 0001787297 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 822729751 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: TWO COMMERCE SQUARE STREET 2: 2001 MARKET STREET, 28TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 BUSINESS PHONE: 2678660312 MAIL ADDRESS: STREET 1: TWO COMMERCE SQUARE STREET 2: 2001 MARKET STREET, 28TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19103 CORRESP 1 filename1.htm

 

Passage Bio, Inc.

Two Commerce Square
2001 Market Street, 28th Floor
Philadelphia, PA 19103

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Healthcare & Insurance

100 F Street, NE

Washington, DC 20549

 

Attention:

 

Ada Sarmento
Joseph McCann
Tara Harkins
Terence O’Brien

 

Re:

 

Passage Bio, Inc.
Registration Statement on Form S-1 (File No. 333-236214) originally filed on February 3, 2020, and corresponding Registration Statement on Form 8-A (File No. 001-39231) filed February 18, 2020

 

Requested Date: February 27, 2020

Requested Time: 4:00 PM Eastern Time

 

Ladies and Gentlemen:

 

Passage Bio, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

 

The Registrant hereby authorizes Robert A. Freedman or Ryan Mitteness, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

 

Should the Staff have additional questions or comments regarding the foregoing, please do not hesitate to contact Mr. Freedman at (650) 335-7292, or, in his absence, Mr. Mitteness at (206) 389-4533.

 

***

 

 

U.S. Securities and Exchange Commission

February 25, 2020

Page 2

 

 

Sincerely,

 

 

 

/s/ Bruce Goldsmith

 

Chief Executive Officer and President

 

Cc                                 Jill M. Quigley, Chief Operating Officer

Edgar B. (Chip) Cale, General Counsel
Passage Bio, Inc.

 

Effie Toshav, Esq.

Robert Freedman, Esq.

Ryan Mitteness, Esq.

Fenwick & West LLP

 

Brent Siler, Esq.

Divakar Gupta, Esq.

Darah Protas, Esq.

Cooley LLP

 

2